Targeting Oncogenic Mutant p53 for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Mutations in the p53 tumor suppressor gene are prevalent in over 50% of human cancers.
• Most p53 mutations are missense, leading to dysfunctional protein accumulation with oncogenic gain-of-function activities.
• Stabilization of mutant p53 enhances cancer cell malignancy, including metastasis and drug resistance.

Purpose of the Study:

• To comprehensively review current strategies targeting oncogenic mutant p53 in cancer therapy.
• To focus on therapeutic approaches that restore wild-type p53 transcriptional activity or reduce mutant p53 levels.

Main Methods:

• Review of existing literature on small-molecule compounds targeting mutant p53.
• Categorization of targeting strategies: restoring wild-type conformation/activity, inducing depletion, inhibiting downstream pathways, and synthetic lethality.
• Emphasis on compounds that restore wild-type p53 transcriptional activity and reduce mutant p53 levels.

Main Results:

• Mutant p53 exhibits oncogenic gain-of-function activities, promoting cancer progression.
• Depletion of mutant p53 can attenuate cancer cell malignant properties.
• Various small-molecule compounds are being developed to target mutant p53 through different mechanisms.

Conclusions:

• Mutant p53 is a druggable target in cancer therapy due to its critical role in oncogenesis.
• Strategies aimed at restoring wild-type p53 function or depleting mutant p53 show therapeutic potential.
• Targeting mutant p53 represents a promising avenue for novel cancer treatments.